Craif Co., Ltd. Craif launches new lung cancer and stomach cancer tests from the “miSignal (R) ️ (My Signa l)” series for early detection of cancer from urinary microRNA

Craif Co., Ltd.
Craif launches new lung cancer and gastric cancer tests from the “miSignal (R)️” series that detects cancer early from urinary microRNA
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as Craif) is a cancer risk screening test service for early detection of cancer from urinary microRNA “miSignal (R) ︎ (My Signal)” series. From October 3, 2022 (Monday), we will start providing stomach cancer and lung cancer tests through medical institutions. As a result, together with the miSignal (R) test for breast cancer and ovarian cancer, which has already been released, it has evolved into a test that can determine the cancer risk of up to 4 types of cancer, and can be recommended to more people. became a service.
[Image

http://misignal.jp/).
About Craif
Craif is a venture company from Nagoya University founded in May 2018. By comprehensively capturing microRNAs from urine using materials that Japan is proud of, combining them with AI (artificial intelligence) and applying them to medical care, we will be able to detect diseases at an early stage and provide personalized medicine, mainly in the area of ​​cancer. We are working on next-generation inspection development to realize Through collaboration with the world’s leading companies and organizations in the medical and healthcare fields, we will promote our vision of “realizing a society where people can live out their natural lives.” For more information, please visit https://craif.com/.

Details about this release:
https://prtimes.jp/main/html/rd/p/000000064.000041883.html


rehow

Leave a Reply

Your email address will not be published.

%d bloggers like this: